We are thrilled to share that the STAMPEDE2 trial has randomised its first patient into Comparison S at the Royal Marsden Hospital Chelsea, on Tuesday 9th July. Comparison S aims to explore the potential benefits of adding Stereotactic Ablative Body Radiotherapy (SABR) to standard of care for men whose prostate cancer has spread to a limited number of body areas. A big thank ...
News
STAMPEDE2 Recruits First Patient
We are delighted to announce that the STAMPEDE2 trial recruited its first patient at the Royal Marsden Hospital Sutton on Friday 21st June. The patient was recruited into Comparison P which is testing the addition of PSMA-Lutetium to standard care. We are full steam ahead trying to activate as many sites as possible across the UK and aim to recruit up to 5000 patients over th ...
June 2024 - Opening of Comparison N Temporarily Paused
Following a change in the STAMPEDE2 trial funding arrangements, the trial has temporarily paused opening the Comparison N (Niraparib) part of the trial. Ongoing updates to the STAMPEDE2 website will reflect this development. Should Comparison N be reinstated in the future, further notifications will be communicated to sites and posted here on the trial website. ...
Applicants Are Now Able to Register to be Associate PI Trainees
Applicants are now able to register to be Associate PI trainees for this study (from 01/03/2024) after having obtained approval from their local PI. Potential Associate PI trainees can find details on how to apply on the Associate PI Scheme website. ...
The STAMPEDE2 Trial Website is Now Live!
We're thrilled to announce the launch of the STAMPEDE2 clinical trial website! While the trial itself is set to go live in spring 2024, our website is ready to provide you with access to insightful details on the trial, its objectives, and the innovative treatments being tested.As we prepare for the imminent launch, we invite you to stay tuned and watch this space for further ...